Key Highlights

  • Shares are up 29.07% pre-market to $6.35, building on a prior close of $4.92.
  • The company's subsidiary, MindWave Innovations, signed a 12-month technology services agreement with Singapore-based AQUAE Holdings.
  • MindWave will build and operate AQUAEChain, a blockchain platform for managing insured ALCI Credits, and stands to earn service fees plus an allocation tied to credits issued on the network.

Apimeds Pharmaceuticals (NYSE American:APUS) shares are up 29.07% pre-market to $6.35, building on a prior close of $4.92, after the company's subsidiary, MindWave Innovations, signed a 12-month technology services agreement with Singapore-based AQUAE Holdings. Under the deal, MindWave will design, develop, deploy, and host AQUAEChain, a platform intended to manage the full lifecycle of ALCI Credits, environmental conservation credits, from issuance and verification through tracking, transfer, and retirement.

MindWave will earn contracted software development and technology service fees, along with an allocation equal to 20% of total ALCI Credits issued and outstanding on the network, calculated quarterly using the company's blockchain issuance ledger. AQUAE will lead the credits methodology, branding, Business development, and partner relationships, while MindWave provides the underlying technology infrastructure and ongoing technical support required to operate the platform.

How the Platform Is Structured

AQUAEChain is designed to bring together blockchain infrastructure, an ALCI Credits registry, monitoring and verification data management, a trading marketplace, and insurance-related features on a single platform. The monitoring tools will collect and analyze project data, including satellite and ground-source information, while the marketplace will support listing, trading, and settlement of credits between AQUAE and its counterparties. All issued credits will be recorded on the company's blockchain ledger, giving AQUAE and its partners a traceable record from issuance to retirement.

Timeline and Contract Structure

The agreement took effect September 14, 2026, with development tied to agreed project milestones. During the initial 12-month term, MindWave will provide platform hosting, infrastructure maintenance, technical escalation support, and embedded engineering assistance. After that term, the parties expect to move to a five-year continuing technology services arrangement, subject to mutual agreement and the execution of definitive documentation.

A Diversification Beyond Core Pharmaceuticals

The deal marks a notable diversification for a company whose core business is Apitox, a bee venom-based biologic therapy currently in Phase 3 trials for knee osteoarthritis, with additional non-registered studies exploring applications in multiple sclerosis. For MindWave, the engagement extends its technology business into environmental and sustainability-focused markets, demonstrating its ability to build and operate specialized digital infrastructure for a client over a multi-year horizon.